Laboratory of Small Animal Surgery (Neurology), School of Veterinary Medicine, Azabu University, Sagamihara, Japan.
Department of Product Development, Bussan Animal Health Co, Ltd, Osaka, Japan.
J Vet Intern Med. 2024 Jul-Aug;38(4):2228-2236. doi: 10.1111/jvim.17108. Epub 2024 May 23.
Zonisamide (ZNS) is a newer generation antiseizure medication (ASM) used to treat epilepsy in dogs and cats. However, scientific and clinical information, particularly regarding monotherapy, is limited.
To evaluate the antiseizure efficacy and tolerability of ZNS monotherapy in dogs with newly diagnosed idiopathic epilepsy (IE).
Study included 56 client-owned dogs newly diagnosed with IE.
This was a prospective multicenter, open-label, uncontrolled study. All dogs were ASM-naïve and had ≥2 seizures within 12 weeks. Dogs were administered 2.7-14.4 mg/kg ZNS PO q12h and followed up for ≥12 weeks. Data from the 12-week maintenance treatment period were compared with those from the 4- to 12-week pretreatment period for efficacy evaluation. Data from the entire ZNS administration period were used to assess tolerability.
Fifty-six dogs were included in our study. Of the dogs, 53 were assessed for efficacy; 40 (76%) had a ≥ 50% reduction in seizure frequency, and 29 (55%) achieved seizure freedom. For 90% of the dogs with ≥50% reduction in seizure frequency, the mean ZNS dose was 4.8 (range, 2.7-8.6) mg/kg q12h and the mean trough plasma ZNS concentration was 18.9 (range, 8.0-48.0) μg/mL. In 7 of the 56 dogs (13%), reduced activity, decreased appetite, vomiting, hindlimb weakness, soft stools, or constipation was observed, albeit mild and temporary. Laboratory tests revealed no relevant changes.
Our study suggests that ZNS monotherapy is effective and well-tolerated in dogs with newly diagnosed IE.
佐尼沙胺（ZNS）是一种新型抗癫痫药物（ASM），用于治疗犬猫癫痫。然而，科学和临床信息，特别是关于单药治疗的信息，是有限的。
评估佐尼沙胺单药治疗新诊断为特发性癫痫（IE）的犬的抗癫痫疗效和耐受性。
本研究纳入了 56 只新诊断为 IE 的患犬。
这是一项前瞻性、多中心、开放标签、非对照研究。所有犬均为 ASM 初治，在 12 周内有≥2 次发作。犬给予 2.7-14.4mg/kg ZNS 口服，每 12 小时 1 次，并随访≥12 周。在疗效评估中，将 12 周维持治疗期的数据与 4-12 周预处理期的数据进行比较。使用整个 ZNS 给药期的数据来评估耐受性。
本研究共纳入 56 只犬。其中 53 只犬的疗效可评估；40 只（76%）的癫痫发作频率降低≥50%，29 只（55%）的癫痫发作停止。对于 90%的癫痫发作频率降低≥50%的犬，平均 ZNS 剂量为 4.8（范围，2.7-8.6）mg/kg，每 12 小时 1 次，平均谷浓度为 18.9（范围，8.0-48.0）μg/ml。在 56 只犬中的 7 只（13%），观察到活动减少、食欲减退、呕吐、后肢无力、软便或便秘，尽管程度较轻且为一过性。实验室检查未发现相关变化。
我们的研究表明，佐尼沙胺单药治疗新诊断为 IE 的犬有效且耐受性良好。
